Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therapeutic Solutions International Creates Disease Specific Therapeutic Platform Based on Gene Editing/Engineering of Inducible Pluripotent Stem Cells

TSOI

Phase III Regenerative Medicine Company Creates Second-Generation Tailor-Made Cellular Therapies

Therapeutic Solutions International reported the successful generation of gene-edited and/or gene-modified regenerative cells possessing mixtures of properties between mesenchymal stem cells and tolerance inducing immune cells. The cellular platform allows for creation of cells that are unique to the disease indication and provide a combination of regenerative as well as tolerogenic activities.

“Conventional mesenchymal stem cells possess great promise, however, unless the cells are specifically created for one purpose, the concept of asking one cell to solve a wide variety of unrelated medical problems can be a bit of a stretch” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “Utilizing iPSC technology, we have been able to generate mesenchymal-like stem cells that are specific for particular disease indications. For example, iPSC derived cells overexpressing pdx-1, in our hands, are approximately 3-5 times more potent at regenerating liver injury in the carbon tetrachloride model.”

The Company has generated and filed intellectual property on a variety of disease-specific modifications of our iPSC line. Importantly, creation of “hybrid cells” which possess tolerogenic and regenerative potential.

“While the Company’s main focus is the Phase III clinical trial using JadiCells for treatment of COVID-19 ARDS and concurrently advancing our pipeline and intellectual property, our focus is to generate the most cutting-edge science we can and accelerate its clinical translation alone or through partnerships.” said Dr. Boris Reznik, Scientific Advisory Board Member of the Company.

As part of the Company’s intellectually property, iPSC derived cells expressing interleukin-27 are described, which appear to potently inhibit pathological immunity and upregulate numerous immunological checkpoints in vitro and in vivo.

“There are parallels between the worlds of immunotherapy and regenerative medicine. The first wave of immunotherapy, interleukin-2 and lymphokine activated killers, had some level of efficacy but were never fully adopted. It was only when the second-generation immunotherapies such as CAR-T and checkpoints came out that cancer immunotherapy was fully accepted,” said Timothy Dixon, President, and CEO of the Company and co-inventor. “I believe that in a similar manner, the field of stem cells will have a renaissance through technologies that are disease specific such as what was disclosed by the Company today.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.